Top Story

C-SWIFT: 8 weeks of therapy may be possible with grazoprevir/elbasvir

April 25, 2015

VIENNA — Patients with cirrhosis as well as genotype 1 and genotype 3 HCV responded favorably to 8 weeks of treatment with a novel grazoprevir and elbasvir-based combination regimen, according to findings presented at the 2015 International Liver Congress.

Fred Poordad, MD, of the Texas Liver Institute and University of Texas Health Science Center in San Antonio, Texas, and colleagues aimed to evaluate a fixed-dose combination of 100 mg grazoprevir and 50 mg elbasvir (MK-5172, MK-8742; Merck) plus 400 mg sofosbuvir (Sovaldi, Gilead) in treatment-naive patients with or without cirrhosis. 

Chikungunya common among US volunteers in Dominican Republic Meeting News Coverage

Chikungunya common among US volunteers in Dominican Republic

April 24, 2015
Infection with chikungunya was common among a group of United States volunteers working in the Dominican Republic during a large outbreak there, according to recent…
Jonathan Mermin In the Journals

HIV infections surge in Indiana

April 24, 2015
INDIANA — Indiana Gov. Mike Pence issued a second 30-day public health disaster emergency today as state and federal health care agencies attempt to contain a…
Meeting News Coverage

EASL releases, outlines 2015 HCV recommendations

April 24, 2015
VIENNA — The goal of HCV therapy is to eradicate infection, according to Jean-Michel Pawlotsky, MD, PhD, Coordinator of the panel that published the 2015 EASL…
FDA News

FDA grants priority review for oral, interferon-free treatment of HCV genotype 4

April 24, 2015
The FDA has accepted AbbVie’s new drug application and granted priority review designation for an all-oral, interferon-free antiviral regimen to treat adult…
More News Headlines »
CME
Conjuctivitis

Management of Pediatric Conjunctivitis and Otitis/Conjunctivitis Syndrome

This activity is supported by an educational grant from Alcon Research, LTD.

Acute bacterial conjunctivitis affects approximately 1 of every 8 children each year, and 5 million cases occur in the…
More »
Meeting News Coverage Video
VIDEO: Assessment of vaccine safety, efficacy critical after introduction

VIDEO: Assessment of vaccine safety, efficacy critical after introduction

April 21, 2015
BETHESDA, Md. — Kathleen M. Neuzil, MD, MPH, director of vaccine access and delivery at PATH in Seattle and…
More »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
morganatic-roan